Vectibix 400 mg (Panitumumab SOLUTION) 400 MG

VECTIBIX 400 MG is a solution containing panitumumab, used for specific medical treatments. This intravenous solution is manufactured by Amgen Canada Inc. and is designed for targeted therapeutic applications.

Strength

400 MG

Pack Size

Manufacturer / TM Owner

AMGEN CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

VECTIBIX 400 MG is primarily used in the treatment of certain types of cancer. Panitumumab, the active ingredient, is a monoclonal antibody that targets specific proteins involved in cancer cell growth. This solution is administered intravenously and is often part of a broader treatment plan for eligible patients.

Side Effects

Common effects of VECTIBIX 400 MG may include skin reactions, fatigue, and gastrointestinal issues. These effects can vary among individuals and are typically monitored by healthcare professionals during treatment. Always consult a healthcare provider for personalized information.

Precautions & Warnings

VECTIBIX 400 MG should be handled with care and administered under medical supervision. It is important to inform healthcare providers about any existing medical conditions or allergies before starting treatment. Proper storage and handling instructions should be followed to maintain the integrity of the solution.

Avoid Interactions

VECTIBIX 400 MG may interact with other medications, including those that affect the immune system. It is crucial to discuss all current medications with a healthcare provider to avoid potential interactions. Always follow the advice of a healthcare professional regarding the use of this solution.

References

Frequently Asked Questions

VECTIBIX 400 MG is used in the treatment of certain types of cancer, targeting specific proteins involved in cancer cell growth.

VECTIBIX 400 MG is administered intravenously by a healthcare professional.

Common effects may include skin reactions, fatigue, and gastrointestinal issues, which should be monitored by a healthcare provider.

VECTIBIX 400 MG is manufactured by Amgen Canada Inc.

It should be handled with care, administered under medical supervision, and stored properly to maintain its integrity.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.